Samil Pharmaceutical

At a glance

Samil Pharmaceutical filed 42 disclosures in the last 12 months, including 10 insider, 4 5% holder, 1 buyback and 1 issuance. The most recent key filing was on Oct 19: Executive bought 1,846 sh on the market at an average ₩8,590, Oct 12.

Revenue for 2025 was ₩210B, down 4.3% on 2024. It made an operating loss of ₩22.2B. Debt was 179% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩103B and operating loss of ₩14.7B.

The 2025 annual report lists 614 employees with an average tenure of 7.2 years and average pay of ₩67.8M, #662 of 1,829 listed companies by average pay. Its 7 directors and auditors were paid ₩295M each on average. It paid no cash dividend for 2025. 허승범 and related parties held 25.92% at year end.

Of 1 recent 5%+ holder report, 0 raised and 0 cut a stake; the largest stake reported was 25.96% on Oct 12.

From the 2025 annual report

Staff: 614 (389 men, 225 women), of whom 18 on fixed-term contracts. Total pay for the year: ₩41.7B. Directors and auditors: 7, paid ₩2.1B in total.

No cash dividend was paid for 2025.

Largest shareholder

허승범 holds 8.20%; with 10 related parties the group holds 25.92% of common shares at year end (from 25.65% at the start of the year).

Individuals paid ₩500M or more

Auditor: 우리회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary

5%+ holder reports